Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and raises the price target from $53 to $74.
May 08, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on Janux Therapeutics and raises the price target from $53 to $74.
The increase in price target by a reputable analyst like Robert Driscoll suggests a strong bullish outlook on Janux Therapeutics, likely leading to positive investor sentiment and a potential short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100